<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Exp Ther Med</journal-id><journal-id journal-id-type="iso-abbrev">Exp Ther Med</journal-id><journal-id journal-id-type="publisher-id">ETM</journal-id><journal-title-group><journal-title>Experimental and Therapeutic Medicine</journal-title></journal-title-group><issn pub-type="ppub">1792-0981</issn><issn pub-type="epub">1792-1015</issn><publisher><publisher-name>D.A. Spandidos</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29285158</article-id><article-id pub-id-type="pmc">5740734</article-id><article-id pub-id-type="doi">10.3892/etm.2017.5325</article-id><article-id pub-id-type="publisher-id">ETM-0-0-5325</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Clinical observation of ulinastatin combined with CRRT in the treatment of early cardiopulmonary resuscitation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Qinghong</given-names></name><xref ref-type="aff" rid="af1-etm-0-0-5325"/></contrib><contrib contrib-type="author"><name><surname>Peng</surname><given-names>Jinliang</given-names></name><xref ref-type="aff" rid="af1-etm-0-0-5325"/></contrib><contrib contrib-type="author"><name><surname>Zhou</surname><given-names>Yuming</given-names></name><xref ref-type="aff" rid="af1-etm-0-0-5325"/></contrib><contrib contrib-type="author"><name><surname>Zeng</surname><given-names>Weilan</given-names></name><xref ref-type="aff" rid="af1-etm-0-0-5325"/></contrib><contrib contrib-type="author"><name><surname>Xiao</surname><given-names>Shihui</given-names></name><xref ref-type="aff" rid="af1-etm-0-0-5325"/></contrib><contrib contrib-type="author"><name><surname>Cheng</surname><given-names>Hui</given-names></name><xref ref-type="aff" rid="af1-etm-0-0-5325"/></contrib><contrib contrib-type="author"><name><surname>Zhong</surname><given-names>Zhenzhou</given-names></name><xref ref-type="aff" rid="af1-etm-0-0-5325"/></contrib><contrib contrib-type="author"><name><surname>Liao</surname><given-names>Xiangming</given-names></name><xref ref-type="aff" rid="af1-etm-0-0-5325"/></contrib><contrib contrib-type="author"><name><surname>Xiao</surname><given-names>Xiaoliu</given-names></name><xref ref-type="aff" rid="af1-etm-0-0-5325"/></contrib><contrib contrib-type="author"><name><surname>Luo</surname><given-names>Liang</given-names></name><xref ref-type="aff" rid="af1-etm-0-0-5325"/></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Xianghong</given-names></name><xref ref-type="aff" rid="af1-etm-0-0-5325"/><xref rid="c1-etm-0-0-5325" ref-type="corresp"/></contrib></contrib-group><aff id="af1-etm-0-0-5325">Department of Emergency, Ganzhou People's Hospital, Ganzhou, Jiangxi 341000, P.R. China</aff><author-notes><corresp id="c1-etm-0-0-5325"><italic>Correspondence to</italic>: Dr Xianghong Liu, Department of Emergency, Ganzhou People's Hospital, 17 Hongqi Avenue, Ganzhou, Jiangxi 341000, P.R. China, E-mail: <email>liuqinghongdr@163.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>12</month><year>2017</year></pub-date><pub-date pub-type="epub"><day>17</day><month>10</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>17</day><month>10</month><year>2017</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>14</volume><issue>6</issue><fpage>6064</fpage><lpage>6068</lpage><history><date date-type="received"><day>28</day><month>6</month><year>2017</year></date><date date-type="accepted"><day>10</day><month>10</month><year>2017</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; Liu et al.</copyright-statement><copyright-year>2017</copyright-year><license license-type="open-access"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivs License</ext-link>, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.</license-p></license></permissions><abstract><p>The clinical efficacy of ulinastatin (UTI) combined with continuous renal replacement therapy (CRRT) in the treatment after early cardiopulmonary resuscitation (CPR) was evaluated. A total of 70 patients who were successfully treated with CPR in Ganzhou People's Hospital from October 2016 to March 2017 were selected as the subjects. The patients were randomly divided into control group (35 cases, conventional treatment) and UTI combined with CRRT group (35 cases, UTI + CRRT). The whole blood of patients was collected at 0, 3, 6 and 12 h after CPR. Reverse transcription-polymerase chain reaction assay was used to detect the changes of toll-like receptor 4 (TLR4) gene in mRNA levels between the two groups, i-STAT system 300 was used to analyze pH level, SO<sub>2</sub>, HCO<sub>3</sub><sup>&#x02212;</sup> and lactic acid (LAC) concentration; Abbott AXSYM system was used to detect the expression of cardiac troponin I (cTnI) in serum; the concentration of plasma malondialdehyde (MDA) was examined by a special kit; interleukin-6 (IL-6) and tumor necrosis factor-&#x003b1; (TNF-&#x003b1;) in patients was determined by enzyme-linked immunosorbent assay. The effect of UTI combined with CRRT in the early stage of CPR was analyzed. The levels of TLR4, cTnI, TNF-&#x003b1;, IL-6 and MDA in the plasma of patients in both groups were significantly increased (P&#x0003c;0.05), but the expression level in UTI + CRRT group was lower than that in control group (P&#x0003c;0.05). Compared with the control group, the HCO<sub>3</sub><sup>&#x02212;</sup> decreased significantly (P&#x0003c;0.05) in the UTI + CRRT group at 3 h, while the pH and SO<sub>2</sub> did not change significantly. UTI + CRRT could significantly shorten the average recovery time of consciousness and the average recovery time of consciousness and spontaneous respiration in patients treated with CPR (P&#x0003c;0.05). Moreover, the score of APACHE II was significantly lower than that of control group (P&#x0003c;0.05). UTI combined with CRRT treatment can significantly improve the patient's condition after early CPR.</p></abstract><kwd-group><kwd>ulinastatin</kwd><kwd>continuous renal replacement therapy</kwd><kwd>cardiopulmonary resuscitation</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Sudden cardiac death is the leading cause of death in the world. Statistics show that in China, the number of sudden cardiac death per year is 544,000 (<xref rid="b1-etm-0-0-5325" ref-type="bibr">1</xref>). Cardiopulmonary resuscitation (CPR) is the most effective way to save the lives of patients. However, CPR still failed to achieve satisfactory results in the treatment of cardiac arrest (CA). The literature reported that 40% of patients undergoing CPR treatment achieved return of spontaneous circulation (ROSC), 10&#x02013;30% of patients were completely cured and discharged, and the remaining patients died of disease (<xref rid="b2-etm-0-0-5325" ref-type="bibr">2</xref>). However, patients with successful rescue can often have a variety of complications, such as permanent neurological complications, including cognitive disorders and dyskinesia (<xref rid="b3-etm-0-0-5325" ref-type="bibr">3</xref>); post-resuscitation cardiac dysfunction is also an important reason leading to poor prognosis of patients (<xref rid="b4-etm-0-0-5325" ref-type="bibr">4</xref>), it manifests as systemic ischemia and reperfusion syndrome. At the same time, due to the sharp increase of a variety of deregulation cytokines in the blood 3 h after CA, such as endotoxin releasing into the plasma, there will be severe sepsis, leading to tissue damage (<xref rid="b5-etm-0-0-5325" ref-type="bibr">5</xref>&#x02013;<xref rid="b7-etm-0-0-5325" ref-type="bibr">7</xref>). Therefore, it is of important clinical significance to explore an effective treatment in order to improve the CPR postoperative prognosis.</p><p>In this experiment, we selected ulinastatin (UTI). UTI is derived from human urinary protease inhibitors (<xref rid="b8-etm-0-0-5325" ref-type="bibr">8</xref>). It has been proved to have anti-inflammatory, inhibiting neutrophil elastase, inhibiting chemokine release and penetration effects (<xref rid="b9-etm-0-0-5325" ref-type="bibr">9</xref>). In addition, UTI protects mitochondrial function by reducing calcium overload in cells, playing a role in the protection of heart, lung, liver, kidney ischemia-reperfusion injury (<xref rid="b10-etm-0-0-5325" ref-type="bibr">10</xref>). However, few studies have evaluated the effect of UTI on cardiac dysfunction after CPR. In the present study, we adopted continuous renal replacement therapy (CRRT) at the same time, analyzed the role of UTI + CRRT in early CPR, to provide some theoretical basis for clinical treatment and improving the prognosis of CA.</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><sec><title/><sec><title>Clinical data</title><p>A total of 70 patients who were treated for CPR in Ganzhou People's Hospital from October 2016 to March 2017 were selected as the subjects. All patients or their families signed informed consent, all procedures were in accordance with the principles set out in the Helsinki Declaration. A total of 70 patients were randomly divided into control group (n=35, male 18, female 17, mean age: 53.71&#x000b1;5.41 years) and UTI combined with CRRT group (UTI + CRRT, n=35, male 19, female 16, mean age: 54.64&#x000b1;14.72 years). According to the American Heart Association guidelines, CPR was performed, if necessary, chest compression and defibrillation was given in reference to Advanced Cardiac Life Support Protocol. The study was approved by the Ethics Committee of Ganzhou People's Hospital.</p><p>Successful recovery was defined as patients showing significant pulse and electrocardiography rhythm as well as ventricular tachycardia or fibrillation. In the control group, patients were treated with conventional symptomatic therapy. In the UTI + CRRT group, patients were treated with intravenous injection of UTI immediately after ROSC (Guangdong Tianpu Biochemical Pharmaceutical Co., Ltd., Guangzhou, China; SFDA approval no. H9990134) (300,000 U dissolved in 20 ml NaCl solution), once every 12 h. At the same time, CRRT treatment was performed with Diapact CRRT (B. Braun Melsungen AG, Melsungen, Germany), 3 times for each patient: Once per day for 3 days, 8 h for each treatment. All patients underwent preoperative and post-resuscitation APACHE II scoring by the same physician.</p></sec><sec><title>Sample collection and testing</title><p>The whole blood samples of the patients were collected at 4 time points (0, 3, 6 and 12 h) after CPR. After collecting them in the sodium citrate anticoagulant tube, the cells were centrifuged for 5 min at 1,500 &#x000d7; g, then preserved at &#x02212;80&#x000b0;C immediately. After all the samples were collected, tumor necrosis factor-&#x003b1; (TNF-&#x003b1;), IL-6, malondialdehyde (MDA) and cardiac troponin I (cTnI) were measured in all samples. Blood samples from patients were analyzed for pH, SO<sub>2</sub>, HCO<sub>3</sub><sup>&#x02212;</sup> and lactic acid (LAC) using i-STAT System 300 (Abbott Laboratories Inc., NY, USA). The cTnI concentration was measured using the Abbott AXSYM system. The MDA content was determined by the kit (Sigma; Merck KGaA, Darmstadt, Germany).</p></sec><sec><title>Detection of serum TNF-&#x003b1; and IL-6 by ELISA</title><p>The levels of TNF-&#x003b1; and IL-6 in the serum of the patients were determined by the ELISA kit (Abcam, Cambridge, MA, USA). The reaction was carried out according to the kit instructions. The reaction product was measured at 450 nm wavelength and the OD values were measured, the expression was analyzed.</p></sec><sec><title>Detection of toll-like receptor 4 (TLR4) expression by RT-PCR</title><p>The lymphocytes in the blood were extracted using the TBD lymphocyte extraction kit (Tiangen Biotech Co., Ltd., Beijing, China), and RNA was extracted using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA). The concentration of extracted RNA was measured using a spectrophotometer, 1 &#x000b5;g of RNA was taken for reverse transcription (Takara Bio, Inc., Otsu, Japan). The mRNA levels of each indicators were determined using SYBR-Green fluorescent reagent (Toyobo Life Science, Osaka, Japan). TLR4 gene primers were synthesized by Sangon Biotech Shanghai Co., Ltd. (Shanghai, China). Sequences: Upstream 5&#x02032;-CGTCTAGTCTAGAGCATCATC-3&#x02032;; downstream 5&#x02032;-GAGAAATGAGGAAGTAAGGG-3&#x02032;; internal reference GAPDH: Upstream 5&#x02032;-AGGTCGGTGTGAACGGATTTG-3&#x02032;; downstream 5&#x02032;-TGTAGACCATGTAGTTGAGGTCA-3&#x02032;. The relative expression level of each index is 2-&#x00394;Cq [&#x00394;Cq = Cq (target gene) - Cq (GAPDH)].</p></sec><sec><title>Statistical analysis</title><p>The results were analyzed using GraphPad Prism software (Version 5.01; GraphPad Software, Inc., San Diego, Chile). The differences of the indicators between the two groups were compared by independent sample t-test. The expression of each indicator at four time points was measured using the variance analysis of repeated measurements. A P&#x0003c;0.05 was considered to indicate a statistically significant difference.</p></sec></sec></sec><sec sec-type="results"><title>Results</title><sec><title/><sec><title>The basic physiological variables of the control and the experimental group</title><p>There was no significant difference in body temperature, heart rate, mean arterial pressure, cardiac defibrillation and basic life support between the two groups (P&#x0003e;0.05) (<xref rid="tI-etm-0-0-5325" ref-type="table">Table I</xref>).</p></sec><sec><title>Evaluation of the difference between the biochemical indicators at different time points between the two groups of patients</title><p>The levels of pH and SaO<sub>2</sub> in the two groups were not significantly different at any time point (P&#x0003e;0.05). Compared with the control group, the levels of HCO<sub>3</sub><sup>&#x02212;</sup> and LAC in the CRRT + UTI group was downregulated significantly at 3 h after ROSC (<xref rid="tII-etm-0-0-5325" ref-type="table">Table II</xref>).</p></sec><sec><title>Serum cTnI and plasma MDA expression</title><p>After CPR, the cTnI in the blood of the two groups showed a continuous upward trend, and MDA reached the peak at 3 h of ROSC. Starting from ROSC 3 h, UTI combined with CRRT significantly reduced the expression of cTnI and MDA (P&#x0003c;0.05) (<xref rid="f1-etm-0-0-5325" ref-type="fig">Fig. 1</xref>).</p></sec><sec><title>RT-PCR detection of TLR4 mRNA levels</title><p>The patient's TLR4 mRNA expression reached the peak 3 h after the CPR, and then decreased. The expression levels of TLR4 mRNA in the CRRT + UTI group were lower than those in the control group at four time points (0, 3, 9, and ROSC 12 h) (P&#x0003c;0.05) (<xref rid="f2-etm-0-0-5325" ref-type="fig">Fig. 2</xref>).</p></sec><sec><title>Detection of the expression of IL-6 and TNF-&#x003b1; by ELISA</title><p>After CPR, the levels of IL-6 and TNF-&#x003b1; in the blood of the two groups reached the peak at 9 h and 3 h of ROSC, respectively. However, the levels of IL-6 and TNF-&#x003b1; in UTI + CRRT were significantly lower than those in the control group (P&#x0003c;0.05) (<xref rid="f3-etm-0-0-5325" ref-type="fig">Fig. 3</xref>).</p></sec><sec><title>Average recovery time of consciousness and spontaneous breathing after CPR</title><p>The average recovery time of consciousness and spontaneous breathing for the patients in UTI combined with CRRT was significantly shorter than the control group (P&#x0003c;0.05) (<xref rid="tIII-etm-0-0-5325" ref-type="table">Table III</xref>).</p></sec><sec><title>APACHE II score of two groups</title><p>APACHE II scores were assessed by designated physicians before and 24 h after CPR. UTI combined with CRRT significantly reduced APACHE II scores (<xref rid="tIV-etm-0-0-5325" ref-type="table">Table IV</xref>).</p></sec></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>After CA occurs in patients, it can lead to various pathological situations, such as inflammation, oxidative stress, myocardial damage and heart damage. In the present study, we analyzed multiple biomarkers at multiple time points after CPR treatment, including cTnI, MDA, TLR4, TNF-&#x003b1;, and IL-6. CTnI is a specific marker of myocardial injury (<xref rid="b11-etm-0-0-5325" ref-type="bibr">11</xref>). Early myocardial injury can be detected by serum cTnI levels (<xref rid="b12-etm-0-0-5325" ref-type="bibr">12</xref>). In the present study, serum cTnI was continuously elevated in both groups, but the level of UTI + CRRT was significantly lower than that of the control group. Changes in cTnI suggest that CA will inevitably lead to myocardial injury in patients, but the use of UTI + CRRT can reduce the damage to a certain extent.</p><p>It has been shown that oxidative stress is associated with lipid peroxidation and is one of the mechanisms of neuronal injury induced by ischemia-reperfusion (<xref rid="b13-etm-0-0-5325" ref-type="bibr">13</xref>,<xref rid="b14-etm-0-0-5325" ref-type="bibr">14</xref>). MDA, as the final product of lipid oxidation, can cause cross-linked polymerization of protein, nucleic acid and other macromolecules, and has cytotoxicity, it is often used as a marker of oxidative stress after ischemia-reperfusion (<xref rid="b15-etm-0-0-5325" ref-type="bibr">15</xref>,<xref rid="b16-etm-0-0-5325" ref-type="bibr">16</xref>). In the present study, plasma MDA levels in both groups increased significantly, reached a peak at 3 h after CPR treatment, and combination of UTI + CRRT significantly decreased MDA content, indicating that UTI and CRRT have protective effects on myocardium after CPR.</p><p>Organ damage CA after successful CRP is considered to associate with systemic inflammatory response; various cytokines and lipopolysaccharide (LPS) levels have been proved to have risen significantly in patients with successful resuscitation (<xref rid="b17-etm-0-0-5325" ref-type="bibr">17</xref>,<xref rid="b18-etm-0-0-5325" ref-type="bibr">18</xref>). TLR4 recognizes LPS, which promotes the production of a variety of inflammatory cytokines (IL-6 and TNF-&#x003b1;), leading to sepsis-like syndrome (<xref rid="b19-etm-0-0-5325" ref-type="bibr">19</xref>). Activated TLR4 promotes nuclear factor expression during cerebral ischemia and hypoxia, and induces the production of cytokines such as TNF-&#x003b1; and IL-6, causing inflammation and nerve damage (<xref rid="b20-etm-0-0-5325" ref-type="bibr">20</xref>). Therefore, we speculate that TLR4 signaling pathway may inhibit the inflammatory response and nerve damage by hypoxic preconditioning, thus protecting brain function. In addition, previous studies have shown that UTI can reduce lung and kidney damage caused by LPS inhibiting the inflammatory response of these organs (<xref rid="b21-etm-0-0-5325" ref-type="bibr">21</xref>). In this study, TLR4 gene was significantly upregulated in both groups after CPR, and TNF-&#x003b1; and IL-6 were also upregulated. UTI combined with CRRT significantly lowered these indicators and shortened the recovery time of consciousness and spontaneous breathing, reduced the APACHE II score.</p><p>In conclusion, we found that UTI combined with CRRT can protect against ischemia/reperfusion injury caused by early CPR, and can inhibit the inflammatory response induced by TLR4 after early CPR.</p></sec></body><back><ref-list><title>References</title><ref id="b1-etm-0-0-5325"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>S</given-names></name></person-group><article-title>Sudden cardiac death in China: Current status and future perspectives</article-title><source>Europace</source><volume>17</volume><fpage>14</fpage><lpage>18</lpage><year>2015</year><pub-id pub-id-type="doi">10.1093/europace/euv143</pub-id></element-citation></ref><ref id="b2-etm-0-0-5325"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Vreede-Swagemakers</surname><given-names>JJ</given-names></name><name><surname>Gorgels</surname><given-names>AP</given-names></name><name><surname>Dubois-Arbouw</surname><given-names>WI</given-names></name><name><surname>van Ree</surname><given-names>JW</given-names></name><name><surname>Daemen</surname><given-names>MJ</given-names></name><name><surname>Houben</surname><given-names>LG</given-names></name><name><surname>Wellens</surname><given-names>HJ</given-names></name></person-group><article-title>Out-of-hospital cardiac arrest in the 1990's: A population-based study in the Maastricht area on incidence, characteristics and survival</article-title><source>J Am Coll Cardiol</source><volume>30</volume><fpage>1500</fpage><lpage>1505</lpage><year>1997</year><pub-id pub-id-type="doi">10.1016/S0735-1097(97)00355-0</pub-id><pub-id pub-id-type="pmid">9362408</pub-id></element-citation></ref><ref id="b3-etm-0-0-5325"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peters</surname><given-names>R</given-names></name><name><surname>Boyde</surname><given-names>M</given-names></name></person-group><article-title>Improving survival after in-hospital cardiac arrest: The Australian experience</article-title><source>Am J Crit Care</source><volume>16</volume><fpage>240</fpage><lpage>246</lpage><year>2007</year><pub-id pub-id-type="pmid">17460315</pub-id></element-citation></ref><ref id="b4-etm-0-0-5325"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>RJ</given-names></name><name><surname>Wu</surname><given-names>E</given-names></name><name><surname>Rafael</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>EL</given-names></name><name><surname>Parker</surname><given-names>MA</given-names></name><name><surname>Simonetti</surname><given-names>O</given-names></name><name><surname>Klocke</surname><given-names>FJ</given-names></name><name><surname>Bonow</surname><given-names>RO</given-names></name><name><surname>Judd</surname><given-names>RM</given-names></name></person-group><article-title>The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction</article-title><source>N Engl J Med</source><volume>343</volume><fpage>1445</fpage><lpage>1453</lpage><year>2000</year><pub-id pub-id-type="doi">10.1056/NEJM200011163432003</pub-id><pub-id pub-id-type="pmid">11078769</pub-id></element-citation></ref><ref id="b5-etm-0-0-5325"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carden</surname><given-names>DL</given-names></name><name><surname>Granger</surname><given-names>DN</given-names></name></person-group><article-title>Pathophysiology of ischaemia-reperfusion injury</article-title><source>J Pathol</source><volume>190</volume><fpage>255</fpage><lpage>266</lpage><year>2000</year><pub-id pub-id-type="doi">10.1002/(SICI)1096-9896(200002)190:3&#x0003c;255::AID-PATH526&#x0003e;3.0.CO;2-6</pub-id><pub-id pub-id-type="pmid">10685060</pub-id></element-citation></ref><ref id="b6-etm-0-0-5325"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hernandez</surname><given-names>LA</given-names></name><name><surname>Grisham</surname><given-names>MB</given-names></name></person-group><article-title>Role of neutrophils in ischemia reperfusion induced microvascular injury</article-title><source>Am J Physiol Heart Circ Physiol</source><volume>3</volume><fpage>699</fpage><lpage>703</lpage><year>2006</year></element-citation></ref><ref id="b7-etm-0-0-5325"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hausenloy</surname><given-names>DJ</given-names></name><name><surname>Yellon</surname><given-names>DM</given-names></name></person-group><article-title>Myocardial ischemia-reperfusion injury: A neglected therapeutic target</article-title><source>J Clin Invest</source><volume>123</volume><fpage>92</fpage><lpage>100</lpage><year>2013</year><pub-id pub-id-type="doi">10.1172/JCI62874</pub-id><pub-id pub-id-type="pmid">23281415</pub-id></element-citation></ref><ref id="b8-etm-0-0-5325"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koga</surname><given-names>Y</given-names></name><name><surname>Fujita</surname><given-names>M</given-names></name><name><surname>Tsuruta</surname><given-names>R</given-names></name><name><surname>Koda</surname><given-names>Y</given-names></name><name><surname>Nakahara</surname><given-names>T</given-names></name><name><surname>Yagi</surname><given-names>T</given-names></name><name><surname>Aoki</surname><given-names>T</given-names></name><name><surname>Kobayashi</surname><given-names>C</given-names></name><name><surname>Izumi</surname><given-names>T</given-names></name><name><surname>Kasaoka</surname><given-names>S</given-names></name><etal/></person-group><article-title>Urinary trypsin inhibitor suppresses excessive superoxide anion radical generation in blood, oxidative stress, early inflammation, and endothelial injury in forebrain ischemia/reperfusion rats</article-title><source>Neurol Res</source><volume>32</volume><fpage>925</fpage><lpage>932</lpage><year>2010</year><pub-id pub-id-type="doi">10.1179/016164110X12645013515133</pub-id><pub-id pub-id-type="pmid">20223106</pub-id></element-citation></ref><ref id="b9-etm-0-0-5325"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Wen</surname><given-names>J</given-names></name><name><surname>Wilbur</surname><given-names>RR</given-names></name><name><surname>Wen</surname><given-names>P</given-names></name><name><surname>Zhou</surname><given-names>SF</given-names></name><name><surname>Xiao</surname><given-names>X</given-names></name></person-group><article-title>The effect of somatostatin, ulinastatin and <italic>Salvia miltiorrhiza</italic> on severe acute pancreatitis treatment</article-title><source>Am J Med Sci</source><volume>346</volume><fpage>371</fpage><lpage>376</lpage><year>2013</year><pub-id pub-id-type="doi">10.1097/MAJ.0b013e31827aa2bc</pub-id><pub-id pub-id-type="pmid">23514667</pub-id></element-citation></ref><ref id="b10-etm-0-0-5325"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pang</surname><given-names>XY</given-names></name><name><surname>Fang</surname><given-names>CC</given-names></name><name><surname>Chen</surname><given-names>YY</given-names></name><name><surname>Liu</surname><given-names>K</given-names></name><name><surname>Song</surname><given-names>GM</given-names></name></person-group><article-title>Effects of ulinastatin on perioperative inflammatory response and pulmonary function in cardiopulmonary bypass patients</article-title><source>Am J Ther</source><volume>23</volume><fpage>e1680</fpage><lpage>e1689</lpage><year>2016</year><pub-id pub-id-type="doi">10.1097/MJT.0000000000000243</pub-id><pub-id pub-id-type="pmid">26938752</pub-id></element-citation></ref><ref id="b11-etm-0-0-5325"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kruzan</surname><given-names>RM</given-names></name><name><surname>Herzog</surname><given-names>CA</given-names></name><name><surname>Wu</surname><given-names>A</given-names></name><name><surname>Sang</surname><given-names>Y</given-names></name><name><surname>Parekh</surname><given-names>RS</given-names></name><name><surname>Matsushita</surname><given-names>K</given-names></name><name><surname>Hwang</surname><given-names>S</given-names></name><name><surname>Cheng</surname><given-names>A</given-names></name><name><surname>Coresh</surname><given-names>J</given-names></name><name><surname>Powe</surname><given-names>NR</given-names></name><etal/></person-group><article-title>Association of NTproBNP and cTnI with outpatient sudden cardiac death in hemodialysis patients: The choices for healthy outcomes in caring for ESRD (CHOICE) study</article-title><source>BMC Nephrol</source><volume>17</volume><fpage>18</fpage><year>2016</year><pub-id pub-id-type="doi">10.1186/s12882-016-0230-x</pub-id><pub-id pub-id-type="pmid">26897129</pub-id></element-citation></ref><ref id="b12-etm-0-0-5325"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>CL</given-names></name><name><surname>Wei</surname><given-names>HY</given-names></name><name><surname>Liu</surname><given-names>ZY</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Liao</surname><given-names>XX</given-names></name><name><surname>Li</surname><given-names>YJ</given-names></name><name><surname>Zhan</surname><given-names>H</given-names></name><name><surname>Jing</surname><given-names>XL</given-names></name><name><surname>Xiong</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>YY</given-names></name><etal/></person-group><article-title>Investigation of the relationship between venticular fibrillation duration and cardiac/neurological damage in a rabbit model of electrically induced arrhythmia</article-title><source>J Trauma</source><volume>69</volume><fpage>1442</fpage><lpage>1447</lpage><year>2010</year><pub-id pub-id-type="doi">10.1097/TA.0b013e3181dbbefc</pub-id><pub-id pub-id-type="pmid">20571450</pub-id></element-citation></ref><ref id="b13-etm-0-0-5325"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murdolo</surname><given-names>G</given-names></name><name><surname>Piroddi</surname><given-names>M</given-names></name><name><surname>Luchetti</surname><given-names>F</given-names></name><name><surname>Tortoioli</surname><given-names>C</given-names></name><name><surname>Canonico</surname><given-names>B</given-names></name><name><surname>Zerbinati</surname><given-names>C</given-names></name><name><surname>Galli</surname><given-names>F</given-names></name><name><surname>Iuliano</surname><given-names>L</given-names></name></person-group><article-title>Oxidative stress and lipid peroxidation by-products at the crossroad between adipose organ dysregulation and obesity-linked insulin resistance</article-title><source>Biochimie</source><volume>95</volume><fpage>585</fpage><lpage>594</lpage><year>2013</year><pub-id pub-id-type="doi">10.1016/j.biochi.2012.12.014</pub-id><pub-id pub-id-type="pmid">23274128</pub-id></element-citation></ref><ref id="b14-etm-0-0-5325"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martindale</surname><given-names>JJ</given-names></name><name><surname>Metzger</surname><given-names>JM</given-names></name></person-group><article-title>Uncoupling of increased cellular oxidative stress and myocardial ischemia reperfusion injury by directed sarcolemma stabilization</article-title><source>J Mol Cell Cardiol</source><volume>67</volume><fpage>26</fpage><lpage>37</lpage><year>2014</year><pub-id pub-id-type="doi">10.1016/j.yjmcc.2013.12.008</pub-id><pub-id pub-id-type="pmid">24362314</pub-id></element-citation></ref><ref id="b15-etm-0-0-5325"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>XY</given-names></name><name><surname>Chow</surname><given-names>CK</given-names></name></person-group><article-title>An improved method for the measurement of malondialdehyde in biological samples</article-title><source>Lipids</source><volume>29</volume><fpage>73</fpage><lpage>75</lpage><year>1994</year><pub-id pub-id-type="doi">10.1007/BF02537094</pub-id><pub-id pub-id-type="pmid">8139400</pub-id></element-citation></ref><ref id="b16-etm-0-0-5325"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esterbauer</surname><given-names>H</given-names></name><name><surname>Schaur</surname><given-names>RJ</given-names></name><name><surname>Zollner</surname><given-names>H</given-names></name></person-group><article-title>Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes</article-title><source>Free Radic Biol Med</source><volume>11</volume><fpage>81</fpage><lpage>128</lpage><year>1991</year><pub-id pub-id-type="doi">10.1016/0891-5849(91)90192-6</pub-id><pub-id pub-id-type="pmid">1937131</pub-id></element-citation></ref><ref id="b17-etm-0-0-5325"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neumar</surname><given-names>RW</given-names></name><name><surname>Nolan</surname><given-names>JP</given-names></name><name><surname>Adrie</surname><given-names>C</given-names></name><name><surname>Aibiki</surname><given-names>M</given-names></name><name><surname>Berg</surname><given-names>RA</given-names></name><name><surname>B&#x000f6;ttiger</surname><given-names>BW</given-names></name><name><surname>Callaway</surname><given-names>C</given-names></name><name><surname>Clark</surname><given-names>RS</given-names></name><name><surname>Geocadin</surname><given-names>RG</given-names></name><name><surname>Jauch</surname><given-names>EC</given-names></name><etal/></person-group><article-title>Post-cardiac arrest syndrome: Epidemiology, pathophysiology, treatment, and prognostication. A consensus statement from the International Liaison Committee on Resuscitation (American Heart Association, Australian and New Zealand Council on Resuscitation, European Resuscitation Council, Heart and Stroke Foundation of Canada, InterAmerican Heart Foundation, Resuscitation Council of Asia, and the Resuscitation Council of Southern Africa); the American Heart Association Emergency Cardiovascular Care Committee; the Council on Cardiovascular Surgery and Anesthesia; the Council on Cardiopulmonary, Perioperative, and Critical Care; the Council on Clinical Cardiology; and the Stroke Council</article-title><source>Circulation</source><volume>118</volume><fpage>2452</fpage><lpage>2483</lpage><year>2008</year><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.108.190652</pub-id><pub-id pub-id-type="pmid">18948368</pub-id></element-citation></ref><ref id="b18-etm-0-0-5325"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erenler</surname><given-names>AK</given-names></name><name><surname>&#x000c7;elik</surname><given-names>S</given-names></name><name><surname>Baydin</surname><given-names>A</given-names></name><name><surname>Tomak</surname><given-names>L</given-names></name><name><surname>KoSargelir</surname><given-names>M</given-names></name><name><surname>Yasti</surname><given-names>A&#x000c7;</given-names></name></person-group><article-title>Outcomes of cardiopulmonary resuscitation in trauma patients in the emergency department</article-title><source>Eur Rev Med Pharmacol Sci</source><volume>19</volume><fpage>2567</fpage><lpage>2571</lpage><year>2015</year><pub-id pub-id-type="pmid">26221883</pub-id></element-citation></ref><ref id="b19-etm-0-0-5325"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janssen</surname><given-names>E</given-names></name><name><surname>Ozcan</surname><given-names>E</given-names></name><name><surname>Liadaki</surname><given-names>K</given-names></name><name><surname>Jabara</surname><given-names>HH</given-names></name><name><surname>Manis</surname><given-names>J</given-names></name><name><surname>Ullas</surname><given-names>S</given-names></name><name><surname>Akira</surname><given-names>S</given-names></name><name><surname>Fitzgerald</surname><given-names>KA</given-names></name><name><surname>Golenbock</surname><given-names>DT</given-names></name><name><surname>Geha</surname><given-names>RS</given-names></name></person-group><article-title>TRIF signaling is essential for TLR4-driven IgE class switching (IRM5P. 707)</article-title><source>J Immunol</source><volume>192</volume><fpage>2651</fpage><lpage>2658</lpage><year>2014</year><pub-id pub-id-type="doi">10.4049/jimmunol.1300909</pub-id><pub-id pub-id-type="pmid">24532577</pub-id></element-citation></ref><ref id="b20-etm-0-0-5325"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blanco</surname><given-names>AM</given-names></name><name><surname>Vall&#x000e9;s</surname><given-names>SL</given-names></name><name><surname>Pascual</surname><given-names>M</given-names></name><name><surname>Guerri</surname><given-names>C</given-names></name></person-group><article-title>Involvement of TLR4/type I IL-1 receptor signaling in the induction of inflammatory mediators and cell death induced by ethanol in cultured astrocytes</article-title><source>J Immunol</source><volume>175</volume><fpage>6893</fpage><lpage>6899</lpage><year>2005</year><pub-id pub-id-type="doi">10.4049/jimmunol.175.10.6893</pub-id><pub-id pub-id-type="pmid">16272348</pub-id></element-citation></ref><ref id="b21-etm-0-0-5325"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Su</surname><given-names>C</given-names></name><name><surname>Qian</surname><given-names>W</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Sun</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name></person-group><article-title>Urinary trypsin inhibitor attenuates LPS-induced endothelial barrier dysfunction by upregulation of vascular endothelial-cadherin expression</article-title><source>Inflamm Res</source><volume>65</volume><fpage>213</fpage><lpage>224</lpage><year>2016</year><pub-id pub-id-type="doi">10.1007/s00011-015-0907-9</pub-id><pub-id pub-id-type="pmid">26681130</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="f1-etm-0-0-5325" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Serum expression of cTnI and plasma. After CPR, cTnI in the blood of the two groups continued to increase, and MDA peaked at 3 h after ROSC. The expression of cTnI and MDA in UTI + CRRT group was significantly lower than that in control group from ROSC 3 h. UTI + CRRT vs. control group, *P&#x0003c;0.05, **P&#x0003c;0.01, ***P&#x0003c;0.001. cTnI, cardiac troponin I; CPR, cardiopulmonary resuscitation; MDA, malondialdehyde; UTI, ulinastatin; CRRT, continuous renal replacement theraphy; ROSC, return of spontaneous circulation.</p></caption><graphic xlink:href="etm-14-06-6064-g00"/></fig><fig id="f2-etm-0-0-5325" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>RT-PCR detection of TLR4 mRNA levels. The patient's TLR4 mRNA expression reached the peak 3 h after the CPR, and then decreased. The expression levels of TLR4 mRNA in the CRRT + UTI were lower than those in the control group at four time points (0 h, 3 h, 9 h and ROSC 12 h) (P&#x0003c;0.05). UTI + CRRT vs. control group, *P&#x0003c;0.05, **P&#x0003c;0.01. RT-PCR, reverse transcription-polymerase chain reaction; TLR4, toll-like receptor 4; CPR, cardiopulmonary resuscitation; CRRT, continuous renal replacement therapy; UTI, ulinastatin; ROSC, return of spontaneous circulation.</p></caption><graphic xlink:href="etm-14-06-6064-g01"/></fig><fig id="f3-etm-0-0-5325" orientation="portrait" position="float"><label>Figure 3.</label><caption><p>ELISA detection of IL-6, and TNF-&#x003b1; expression. After CPR, the levels of IL-6 and TNF-&#x003b1; in the blood of the two groups reached the peak at 9 h and 3 h of ROSC, respectively. However, the levels of IL-6 and TNF-&#x003b1; in UTI + CRRT group were significantly lower than those in control group. UTI + CRRT group vs. control group, *P&#x0003c;0.05. TNF-&#x003b1;, tumor necrosis factor-&#x003b1;; IL-6, interleukin-6, CPR, cardiopulmonary resuscitation; ROSC, return of spontaneous circulation; UTI, ulinastatin; CRRT, continuous renal replacement theraphy.</p></caption><graphic xlink:href="etm-14-06-6064-g02"/></fig><table-wrap id="tI-etm-0-0-5325" orientation="portrait" position="float"><label>Table I.</label><caption><p>Baseline physiology and resuscitation related variables (mean &#x000b1; SD).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Item</th><th align="center" valign="bottom" rowspan="1" colspan="1">Control (n=35)</th><th align="center" valign="bottom" rowspan="1" colspan="1">UTI + CRRT (n=35)</th><th align="center" valign="bottom" rowspan="1" colspan="1">t-test</th><th align="center" valign="bottom" rowspan="1" colspan="1">P-value</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Age</td><td align="center" valign="top" rowspan="1" colspan="1">46.54&#x000b1;7.62</td><td align="center" valign="top" rowspan="1" colspan="1">48.02&#x000b1;9.33</td><td align="center" valign="top" rowspan="1" colspan="1">2.473</td><td align="center" valign="top" rowspan="1" colspan="1">0.883</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sex</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;Male</td><td align="center" valign="top" rowspan="1" colspan="1">17</td><td align="center" valign="top" rowspan="1" colspan="1">19</td><td align="center" valign="top" rowspan="1" colspan="1">3.234</td><td align="center" valign="top" rowspan="1" colspan="1">0.673</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;Female</td><td align="center" valign="top" rowspan="1" colspan="1">18</td><td align="center" valign="top" rowspan="1" colspan="1">16</td><td align="center" valign="top" rowspan="1" colspan="1">3.667</td><td align="center" valign="top" rowspan="1" colspan="1">0.594</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Body temperature (&#x000b0;C)</td><td align="center" valign="top" rowspan="1" colspan="1">37.7&#x000b1;0.4</td><td align="center" valign="top" rowspan="1" colspan="1">37.5&#x000b1;0.6</td><td align="center" valign="top" rowspan="1" colspan="1">0.968</td><td align="center" valign="top" rowspan="1" colspan="1">0.753</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HR (times/min)</td><td align="center" valign="top" rowspan="1" colspan="1">263&#x000b1;20</td><td align="center" valign="top" rowspan="1" colspan="1">270&#x000b1;22</td><td align="center" valign="top" rowspan="1" colspan="1">0.889</td><td align="center" valign="top" rowspan="1" colspan="1">0.832</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MAP (mm/Hg)</td><td align="center" valign="top" rowspan="1" colspan="1">85&#x000b1;9</td><td align="center" valign="top" rowspan="1" colspan="1">87&#x000b1;11</td><td align="center" valign="top" rowspan="1" colspan="1">0.802</td><td align="center" valign="top" rowspan="1" colspan="1">0.477</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DF (times)</td><td align="center" valign="top" rowspan="1" colspan="1">3&#x000b1;1</td><td align="center" valign="top" rowspan="1" colspan="1">3&#x000b1;1</td><td align="center" valign="top" rowspan="1" colspan="1">0.661</td><td align="center" valign="top" rowspan="1" colspan="1">0.482</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BLS (min)</td><td align="center" valign="top" rowspan="1" colspan="1">3.7&#x000b1;2.0</td><td align="center" valign="top" rowspan="1" colspan="1">3.6&#x000b1;1.8</td><td align="center" valign="top" rowspan="1" colspan="1">0.539</td><td align="center" valign="top" rowspan="1" colspan="1">0.724</td></tr></tbody></table><table-wrap-foot><fn id="tfn1-etm-0-0-5325"><p>HR, heart rate; MAP, mean arterial pressure; DF, cardiac defibrillation; BLS, basic life support; SD, standard deviation.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tII-etm-0-0-5325" orientation="portrait" position="float"><label>Table II.</label><caption><p>Comparison of biochemical indicators in two groups (mean &#x000b1; SD).</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th align="center" valign="bottom" colspan="6" rowspan="1">ROSC</th></tr><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th align="center" valign="bottom" colspan="6" rowspan="1"><hr/></th></tr><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Groups</th><th align="center" valign="bottom" rowspan="1" colspan="1">Index</th><th align="center" valign="bottom" rowspan="1" colspan="1">0 h</th><th align="center" valign="bottom" rowspan="1" colspan="1">3 h</th><th align="center" valign="bottom" rowspan="1" colspan="1">6 h</th><th align="center" valign="bottom" rowspan="1" colspan="1">12 h</th><th align="center" valign="bottom" rowspan="1" colspan="1">F-value</th><th align="center" valign="bottom" rowspan="1" colspan="1">P-value</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Control</td><td align="left" valign="top" rowspan="1" colspan="1">pH</td><td align="center" valign="top" rowspan="1" colspan="1">7.25&#x000b1;0.04</td><td align="center" valign="top" rowspan="1" colspan="1">7.26&#x000b1;0.05</td><td align="center" valign="top" rowspan="1" colspan="1">7.28&#x000b1;0.07</td><td align="center" valign="top" rowspan="1" colspan="1">7.25&#x000b1;0.04</td><td align="center" valign="top" rowspan="1" colspan="1">1.352</td><td align="center" valign="top" rowspan="1" colspan="1">0.236</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">(n=35)</td><td align="left" valign="top" rowspan="1" colspan="1">SaO<sub>2</sub> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">94&#x000b1;2</td><td align="center" valign="top" rowspan="1" colspan="1">94&#x000b1;3</td><td align="center" valign="top" rowspan="1" colspan="1">93&#x000b1;4</td><td align="center" valign="top" rowspan="1" colspan="1">93&#x000b1;3</td><td align="center" valign="top" rowspan="1" colspan="1">1.023</td><td align="center" valign="top" rowspan="1" colspan="1">0.991</td></tr><tr><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">HCO<sub>3</sub><sup>&#x02212;</sup></td><td align="center" valign="top" rowspan="1" colspan="1">34&#x000b1;3</td><td align="center" valign="top" rowspan="1" colspan="1">30&#x000b1;3</td><td align="center" valign="top" rowspan="1" colspan="1">27&#x000b1;4</td><td align="center" valign="top" rowspan="1" colspan="1">23&#x000b1;5</td><td align="center" valign="top" rowspan="1" colspan="1">0.420</td><td align="center" valign="top" rowspan="1" colspan="1">0.621</td></tr><tr><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">(mmol/l)</td><td align="center" valign="top" rowspan="1" colspan="1">7.46&#x000b1;2.15</td><td align="center" valign="top" rowspan="1" colspan="1">6.04&#x000b1;2.02</td><td align="center" valign="top" rowspan="1" colspan="1">5.53&#x000b1;2.68</td><td align="center" valign="top" rowspan="1" colspan="1">3.92&#x000b1;2.66</td><td align="center" valign="top" rowspan="1" colspan="1">0.524</td><td align="center" valign="top" rowspan="1" colspan="1">0.268</td></tr><tr><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Lac (mmol/l)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CRRT + UTI</td><td align="left" valign="top" rowspan="1" colspan="1">pH</td><td align="center" valign="top" rowspan="1" colspan="1">7.24&#x000b1;0.04</td><td align="center" valign="top" rowspan="1" colspan="1">7.25&#x000b1;0.06</td><td align="center" valign="top" rowspan="1" colspan="1">7.26&#x000b1;0.08</td><td align="center" valign="top" rowspan="1" colspan="1">7.24&#x000b1;0.05</td><td align="center" valign="top" rowspan="1" colspan="1">1.0839</td><td align="center" valign="top" rowspan="1" colspan="1">0.738</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">group (n=35)</td><td align="left" valign="top" rowspan="1" colspan="1">SaO<sub>2</sub> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">95&#x000b1;3</td><td align="center" valign="top" rowspan="1" colspan="1">94&#x000b1;4</td><td align="center" valign="top" rowspan="1" colspan="1">95&#x000b1;4</td><td align="center" valign="top" rowspan="1" colspan="1">93&#x000b1;4</td><td align="center" valign="top" rowspan="1" colspan="1">0.832</td><td align="center" valign="top" rowspan="1" colspan="1">0.651</td></tr><tr><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">HCO<sub>3</sub><sup>&#x02212;</sup></td><td align="center" valign="top" rowspan="1" colspan="1">34&#x000b1;4</td><td align="center" valign="top" rowspan="1" colspan="1">25&#x000b1;4<sup><xref rid="tfn3-etm-0-0-5325" ref-type="table-fn">a</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">19&#x000b1;5<sup><xref rid="tfn4-etm-0-0-5325" ref-type="table-fn">b</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">17&#x000b1;4<sup><xref rid="tfn3-etm-0-0-5325" ref-type="table-fn">a</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">7.453</td><td align="center" valign="top" rowspan="1" colspan="1">0.0326</td></tr><tr><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">(mmol/l)</td><td align="center" valign="top" rowspan="1" colspan="1">7.51&#x000b1;2.42</td><td align="center" valign="top" rowspan="1" colspan="1">4.06&#x000b1;1.83<sup><xref rid="tfn3-etm-0-0-5325" ref-type="table-fn">a</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">3.08&#x000b1;1.7<sup><xref rid="tfn3-etm-0-0-5325" ref-type="table-fn">a</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">2.74&#x000b1;1.50<sup><xref rid="tfn3-etm-0-0-5325" ref-type="table-fn">a</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">6.883</td><td align="center" valign="top" rowspan="1" colspan="1">0.0192</td></tr><tr><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Lac (mmol/l)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="tfn2-etm-0-0-5325"><p>UTI + CRRT vs. control group</p></fn><fn id="tfn3-etm-0-0-5325"><label>a</label><p>P&#x0003c;0.05</p></fn><fn id="tfn4-etm-0-0-5325"><label>b</label><p>P&#x0003c;0.01. ROSC, return of spantaneous circulation; Lac, lactic acid; CRRT, continuous renal replacement theraphy; UTI, ulinastatin; SD, standard deviation.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tIII-etm-0-0-5325" orientation="portrait" position="float"><label>Table III.</label><caption><p>The time of recovery of consciousness and spontaneous breathing (h) (mean &#x000b1; SD).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Groups</th><th align="center" valign="bottom" rowspan="1" colspan="1">n</th><th align="center" valign="bottom" rowspan="1" colspan="1">Average recovery time of spontaneous breathing</th><th align="center" valign="bottom" rowspan="1" colspan="1">Average recovery time of consciousness</th><th align="center" valign="bottom" rowspan="1" colspan="1">t-test</th><th align="center" valign="bottom" rowspan="1" colspan="1">P-value</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Control</td><td align="center" valign="top" rowspan="1" colspan="1">35</td><td align="center" valign="top" rowspan="1" colspan="1">15&#x000b1;7.2</td><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">36&#x000b1;11.2</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CRRT + UTI</td><td align="center" valign="top" rowspan="1" colspan="1">35</td><td align="center" valign="top" rowspan="1" colspan="1">33&#x000b1;8.5<sup><xref rid="tfn7-etm-0-0-5325" ref-type="table-fn">b</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">52&#x000b1;12.5<sup><xref rid="tfn6-etm-0-0-5325" ref-type="table-fn">a</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">2.604</td><td align="center" valign="top" rowspan="1" colspan="1">0.0204</td></tr></tbody></table><table-wrap-foot><fn id="tfn5-etm-0-0-5325"><p>UTI + CRRT vs. control group</p></fn><fn id="tfn6-etm-0-0-5325"><label>a</label><p>P&#x0003c;0.05</p></fn><fn id="tfn7-etm-0-0-5325"><label>b</label><p>P&#x0003c;0.01. CRRT, continuous renal replacement theraphy; UTI, ulinastatin; SD, standard deviation.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tIV-etm-0-0-5325" orientation="portrait" position="float"><label>Table IV.</label><caption><p>APACHE II score (mean &#x000b1; SD).</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th align="center" valign="bottom" colspan="3" rowspan="1">APACHE II score (points)</th></tr><tr><th rowspan="1" colspan="1"/><th align="center" valign="bottom" colspan="3" rowspan="1"><hr/></th></tr><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Groups</th><th align="center" valign="bottom" rowspan="1" colspan="1">n</th><th align="center" valign="bottom" rowspan="1" colspan="1">Before</th><th align="center" valign="bottom" rowspan="1" colspan="1">After</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Control</td><td align="center" valign="top" rowspan="1" colspan="1">35</td><td align="center" valign="top" rowspan="1" colspan="1">24.41&#x000b1;4.41</td><td align="center" valign="top" rowspan="1" colspan="1">21.34&#x000b1;6.23</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">UTI + CRRT</td><td align="center" valign="top" rowspan="1" colspan="1">35</td><td align="center" valign="top" rowspan="1" colspan="1">24.57&#x000b1;5.34</td><td align="center" valign="top" rowspan="1" colspan="1">16.60&#x000b1;8.49<sup><xref rid="tfn9-etm-0-0-5325" ref-type="table-fn">a</xref></sup></td></tr></tbody></table><table-wrap-foot><fn id="tfn8-etm-0-0-5325"><p>UTI + CRRT vs. control group</p></fn><fn id="tfn9-etm-0-0-5325"><label>a</label><p>P&#x0003c;0.01. CRRT, continuous renal replacement theraphy; UTI, ulinastatin; SD, standard deviation.</p></fn></table-wrap-foot></table-wrap></floats-group></article>